Ashish Sharma

Employment

• Lotus Eye Hospital and Institute Consultant

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (101)

• Photic retinal injury: Time to move beyond case reports—A PRISM Study Group perspective
  Eye 2026 DOI: 10.1038/s41433-026-04778-6
  +Save
• Real-world effectiveness and safety of ranibizumab biosimilar FYB-201 in Saudi Arabia (Ravegza) and Jordan (Uptera): a middle eastern extension of the FORCE study
  Eye 2026 DOI: 10.1038/s41433-026-04537-7
  +Save
• Rethinking phase III trials in retinal biosimilars: Do we still need them?
  Eye 2026 DOI: 10.1038/s41433-026-04480-7
  +Save
• Aflibercept 2 mg Biosimilar (aflibercept-ayyh, Pavblu): Experience of safety in clinical settings-APEX- safety study
  Eye 2026 DOI: 10.1038/s41433-026-04327-1
  +Save
• Aflibercept vs ranibizumab biosimilars: manufacturing differences that might matter in the long run
  Eye 2026 DOI: 10.1038/s41433-025-04167-5
  +Save
• FYB-201 Biosimilar ranibizumab (Ongavia/Ranivisio/Cimerli) Efficacy and Safety in Clinical Settings – FORCE study
  Eye 2025 DOI: 10.1038/s41433-025-04030-7
  +Save
• Aflibercept 2 mg biosimilar (Tyalia)—real-world experience from IRAN (ATRIA study)
  Eye 2025 DOI: 10.1038/s41433-025-03813-2
  +Save
• Biosimilar Ranibizumab (Ranieyes) Safety and Efficacy in the Real World: BRESER Study
  Journal of VitreoRetinal Diseases 2025 DOI: 10.1177/24741264251322213
  +Save
• Aflibercept 2 mg biosimilars—will they lead the Anti-VEGF biosimilar world globally
  Eye 2025 DOI: 10.1038/s41433-025-03732-2
  +Save
• Anti-VEGF Biosimilars for Retinal Diseases Survey 2023- India (Bio-INDAS) by the International Retina Biosimilar Study Group (Inter-BIOS Group) in collaboration with the Vitreo-Retinal Society of India (VRSI)
  Eye 2024 DOI: 10.1038/s41433-024-03284-x
  +Save